Medicines production

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs.

Takeda Pharmaceutical Company Limited (TSE: 4502) and Cardurion Pharmaceuticals today announced the creation of a new cardiovascular development partnership.

Roche today announced that the US FDA has granted breakthrough therapy designation for Venclexta® (venetoclax) in combination with low dose cytarabine (LDAC) for elderly patients with previously untreated AML who are ineligible for intensive chemotherapy.

Roche announced today that OCREVUS® (ocrelizumab) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)

Amgen today announced the submission of a sNDA to the U.S. FDA and a variation to the marketing application to the EMA to include OS data from the Phase 3 head-to-head ENDEAVOR trial in the product information for KYPROLIS® (carfilzomib).

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk

Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States.

PureTech Health's Vedanta Biosciences Granted U.S. Patent Broadly Covering Methods of Treatment with Therapeutics Based on Bacterial Spore Fractions of Microbiota Obtained From Human Donors

The Hungarian Government will financing the pharmaceuticals requirements of St. Joseph’s Clinic Erbil, which is treating Iraqi Christians, for a period of six months.

For the first time, research shows cannabidiol can reduce—and even stop—seizures in a small number of children with severe epilepsy.

The loan agreement has been signed today in Luxemburg.

The new FlexFactory will help Dr. Reddy’s increase its capacity to meet both the expected growth of its currently marketed biosimilars as well as support the launch of a significant portfolio of new biosimilar products in the years to come.

The Canadian Bioceutical Corporation (the “Company” or “BCC”) (CSE:BCC) (OTC:CBICF) today announced that the Company has signed non-binding Letters of Intent (LOI’s) to acquire up to four cannabis enterprises in Arizona and Maryland.

Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age